Work

Pos0618 Beyond Screening for Pulmonary Arterial Hypertension: the Detect Score Is a Promising Prediction Tool for All-cause Mortality in Systemic Sclerosis

Year: 2025
Type: conference-abstract
Abstract: Background: Systemic sclerosis (SSc) is a rare connective tissue disease associated with an increased mortality, due to both SSc-related and non-related causes. Developing prognostic tools to identify patients at increased mortality risk is a pivotal step to prompt more intensive treatment and management. Among them, the SCOpE Score is currently the most robust discriminative tool available for predicting mortality at 3 years (AUC 0.79, 95% CI 0.75 to 0.81) [1]. However, its calculation requires 14 variables, making it difficult to apply in everyday clinical use. The DETECT score is a 2-step screening algorithm for pulmonary arterial hypertension (PAH), which is currently recommended in international guidelines [2] to be performed yearly for SSc patients. Interestingly, most of the variables included in the DETECT score are prognostic factors for mortality in SSc. Objectives: Therefore, we aimed to investigate the DETECT step 2 score as prediction tool for all-cause mortality. Additionally, we compared its accuracy and discriminative power with the established mortality prediction model SCOpE score and determined cut-off values to best predict mortality at 3, 5 and 10 years. Methods: SSc patients from our local EUSTAR cohort were eligible if classified according to the 2013 ACR/EULAR criteria, having available longitudinal follow-up and data to calculate both the DETECT step 2 and the SCOpE scores. The primary outcome was overall mortality, with the baseline visit set to the first timepoint with available data to calculate the DETECT and SCOpE scores. Patients were observed until "death" or "last observation with alive status", with date of the event collected for both. The predictive value of the DETECT-Score on overall mortality over time in SSc patients was tested with a uni- and multivariable Cox proportional hazards regression model, corrected for the known confounder SCOpE score (including 14 known predictors for mortality, such as age and sex). To test for collinearity between the DETECT step 2 and SCOpE scores, a Spearman correlation test was applied, with collinearity defined as r>|0.7|. Given the strong association of DETECT score with presence of PAH, as well as the strong impact of PH on mortality, we performed a first sensitivity analysis after excluding patients with mPAP>20 mmHg on right heart catheterization at any timepoint during the observation (defined as PH patients). An additional sensitivity analysis focused on mortality at 3 years. A time dependent ROC Curve analysis was used to determine the accuracy of the DETECT step 2 score to predict mortality and to define cut offs for the DETECT score to identify patients at high mortality risk at 3, 5 and 10 years. To derive conservative cut offs, PAH patients were excluded from this analysis. The discriminative power was evaluated by comparing the area under the time dependent ROC-Curve of the DETECT step 2 and SCOpE scores at 3, 5 and 10 years. Results: In our cohort, 605 SSc patients fulfilled the inclusion criteria: 505 (83%) were female, 60 (10%) patients were diagnosed with PAH (during follow up), 259 (43%) had ILD and 122 (20%) had diffuse cutaneous disease. Overall, the mean DETECT step 2 and SCOpE scores at baseline were 33.7 ± 9.4 resp. 6.7±5.2. Over a median follow up of 6 (2.6-10.6) years, 82 (14%) patients died. We found a moderate correlation between the DETECT step 2 and SCOpE-Score (r=0.570, 95% CI 0.507 to 0.619). The univariable Cox regression showed a positive association of the DETECT step 2 score with overall mortality (HR 1.090, 95% CI 1.074 to 1.105). The multivariable Cox regression model including the SCOpE-Score confirmed the DETECT step 2 score as an independent predictor for all-cause mortality over time (HR 1.048, 95% CI 1.029 to 1.068). Comparable results were obtained when focusing on mortality at 3 years, as well as after excluding PAH patients (Figure 1). The time-dependent ROC curves analysis showed optimal accuracy to identify mortality risk for both the DETECT step 2 and the SCOpE scores, all with an AUC over 0.93 (Figure 2). When competing the two scores, we observed no significant difference in discriminative power at 3 (ΔAUC=0.025, 95%CI -0.096 to 0.045), 5 (ΔAUC=0.0175, 95%CI -0.070 to 0.035) and at 10 years (ΔAUC=0.006, 95% (-0.041 to 0.0291) (further information are presented in Figure 2). After excluding patients with PAH at any timepoint during observation, we observed that a DETECT step 2 score of 40 showed very good performance in predicting mortality at 3, 5 and 10 years, all resulting in sensitivity of 1.0 and specificity of 0.88. Conclusion: Our study showed that the DETECT step 2 score is a robust prognostic tool to predict overall mortality in SSc, with comparable discriminative power to the SCOpE score and independent from presence of PAH. Finally, a cut-off for the DETECT step 2 score over 40 points showed high accuracy (both sensitivity and specificity above 85%). These findings add further usefulness to the calculation of the DETECT step 2 score in clinical practice, performing well both as a screening tool for PAH and as a stratifying algorithm for high-risk mortality. REFERENCES: [1] Elhai, M. et al. Ann. Rheum. Dis. 76, 1897–1905 (2017). [2] Coghlan, JG et al. Ann Rheum. Dis. 73, 1340 –1349 (2014). Acknowledgements: NIL . Disclosure of Interests: Florian Käs: None declared, Gesa Sauer: None declared, Lorenzo Tofani: None declared, Mike O. Becker Speaker fees: Vifor, Novartis, GSK, Grant/research support from Novartis Foundation for Bio-Medical Research, Foundation for research in Rheumatology (FOREUM), Congress Support from Vifor, GSK, Rucsandra Dobrota Actelion, Boehringer-Ingelheim, Pfizer, Actelion, Iten-Kohaut foundation, Walter und Gertrud Siegenthaler Fellowship, congress participation support from Amgen, Otsuka, Muriel Elhai Speaker fees: Boehringer Ingelheim, Last three years: Grant/research support from Pfizer, Novartis Foundation for Bio-Medical Research, Iten Kohaut foundation, Kurt und Senta Herrmann foundation, Foundation for research in Rheumatology (FOREUM), University Zurich, Walter and Gertrud Siegenthaler Foundation, Theodor und Ida Herzog-Egli – Stiftung and Association des Sclérodermiques de France (ASF). Congress Support from Astrazeneca and Janssen, Carina Mihai Medbase, MED Talks Switzerland, Mepha, MedTrix, Novartis, PlayToKnow, Boehringer Ingelheim und Janssen, Sinziana Muraru: None declared, Anna-Maria Hoffmann-Vold Boehringer Ingelheim, Janssen, Medscape, Merck Sharp & Dohme, Novartis and Roche, AbbVie, ARXX, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Janssen, Medscape, Merck Sharp & Dohme, Pliant Therapeutics, Roche and Werfen, Boehringer Ingelheim, Janssen, Oliver Distler 4P-Pharma, Abbvie, Acceleron, Acepodia Biotech, Aera, Alcimed, Altavant, Amgen, AnaMar, Anaveon AG, Argenx, AstraZeneca, Blade, Bayer, Boehringer Ingelheim, Calluna (Arxx), Cantargia AB, Catalyze Capital, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, Horizon, Janssen, Kymera, Lupin, Medscape, MSD Merck, Miltenyi Biotec, Mitsubishi Tanabe, Nkarta Inc., Novartis, Orion, Pilan, Prometheus, Quell, Redxpharma, Roivant, EMD Serono, Topadur and UCB, Patent issued "mir-29 for the treatment of systemic sclerosis" (US8247389, EP2331143). Co-founder of CITUS AG, 4P-Pharma, Abbvie, Acceleron, Acepodia Biotech, Aera, Alcimed, Altavant, Amgen, AnaMar, Anaveon AG, Argenx, AstraZeneca, Blade, Bayer, Boehringer Ingelheim, Calluna (Arxx), Cantargia AB, Catalyze Capital, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, Horizon, Janssen, Kymera, Lupin, Medscape, MSD Merck, Miltenyi Biotec, Mitsubishi Tanabe, Nkarta Inc., Novartis, Orion, Pilan, Prometheus, Quell, Redxpharma, Roivant, EMD Serono, Topadur and UCB, BI, Kymera, Mitsubishi Tanabe, UCB, Dr. Cosimo Bruni Congress support from Boehringer-Ingelheim, Hartmann-Muller Foundation, Boehringer Ingelheim, Novartis Foundation for medical-biological research, EMDO Foundation, Iten-Kohaut Foundation. Educational grants from Wellcome Trust. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,870
OpenAlex ID: W4411397828
Cites:
Cited by:
Related to: 10